Table 2.
Patient characteristics in propensity matched cohorts
| Non-HCT | Allo-HCT | P | |
|---|---|---|---|
| n | 58 | 58 | |
| Age, y, median (range) | 51 (19-73) | 49.5 (19-71) | >.05 |
| Male sex, n (%) | 30 (52) | 31 (53) | >.05 |
| Year diagnosed, n (%) | >.05 | ||
| 2001-2009 | 18 (31) | 17 (29) | |
| 2010-2018 | 40 (69) | 41 (71) | |
| ECOG performance status, n (%) | >.05 | ||
| 0 | 15 (26) | 20 (34) | |
| 1 | 39 (67) | 37 (64) | |
| ≥2 | 4 (7) | 1 (2) | |
| KPS < 90%, n (%) | 13 (22) | 12 (21) | >.05 |
| WBC at diagnosis, n (%) | >.05 | ||
| <30 000 | 36 (62) | 26 (45) | |
| 30 000-100 000 | 13 (22) | 19 (33) | |
| >100 000 | 9 (16) | 13 (22) | |
| BM blasts, median (range) | 85 (4-98) | 82 (30-98) | >.05 |
| CNS involvement, n (%) | 4 (7) | 7 (12) | >.05 |
| BCR-ABL p190 transcript, n (%) | 48 (83) | 39 (81) | >.05 |
| Other cytogenetic changes, n (%) | 26 (45) | 27 (47) | |
| First-line TKI, n (%) | >.05 | ||
| Imatinib | 16 (28) | 25 (43) | |
| Dasatinib | 37 (64) | 27 (47) | |
| Ponatinib | 5 (9) | 6 (10) |